Previous studies have demonstrated tivantinib prolonged progression-free survival and overall survival in hepatocellular carcinoma.
Patients were enrolled regardless of portal vein thrombosis status and were unable to tolerate other curative therapies.
The 1-year control rate was 99%, the 2-year control rate was 95%, and the median time to progression was 9 months.
The combination of axitinib and TACE is safe and potentially efficacious for patients with inoperable hepatocellular carcinoma.
Regorafenib, a multikinase inhibitor, was approved by the FDA for the treatment of hepatocellular carcinoma after prior sorafenib therapy.
The Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score was highly predictive of hepatocellular carcinoma (HCC) recurrence risk.
Polycystic kidney disease (PKD) may increase one's risk of developing cancer of the liver, colon, and kidney.
The kinase inhibitor regorafenib conferred improved overall survival in patients with unresectable hepatocellular carcinoma (HCC).
For patients with hepatocellular carcinoma, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved survival.
Treatment with sorafenib is not effective in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
People who have three or more alcoholic drinks per day could be raising their odds for liver cancer.
Survival rates are improving for many people with cancers of the breast, prostate, lung, liver, and colon or rectum.
Addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.
By analyzing data from international databases, researchers develop an alternative to the Child-Pugh system.
Safety and efficacy of sorafenib, the standard of care for advanced hepatocellular carcinoma, in older patients, evaluated.
Patients with liver cancer whose tumors cells have less differentiated mesenchymal phenotype and CD44 are less likely to respond to sorafenib.
Heavier people might be more prone to liver cancer, insulin problems.
NANETS: Radical Resection of Pancreatic Neuroendocrine Tumors with Liver Mets Often Prolongs SurvivalOctober 10, 2014
Poorly differentiated pancreatic neuroendocrine carcinoma (PNEC) grade 3 tumors demonstrate lower survival after radical resection of PNETs.
Researchers have discovered that a protein called apoptosis inhibitor of macrophage (AIM) prevents tumor development in liver cells.
Sorafenib Plus Selective Internal Radiation Therapy (SIRT) Improves Survival for Patients with Liver CancerSeptember 10, 2014
Patients with advanced hepatocellular carcinoma may benefit from combined therapy of sorafenib and selective internal radiation therapy.
Researchers found no survival difference found between patients receiving everolimus or placebo.
The benefits of hepatocellular carcinoma screening are unclear in patients with chronic liver disease.
A new study in Western Europeans shows that vitamin D lowers the risk of developing hepatocellular carcinoma.
Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma.
Measurement of α-fetoprotein detects hepatocellular carcinoma most accurately in patients without hepatitis C virus infection.
Celsion announced updated results from its HEAT Study post-hoc analysis which examined the use of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC).
The FDA has approved Guerbet's Lipiodol (ethiozed oil) injection for imaging of hepatocellular carcinoma tumors
Increased coffee consumption may reduce hepatocellular carcinoma risk across ethnicities, according to a study presented at the AACR Annual Meeting.
Coffee consumption is associated with a 40% reduction in the risk of liver cancer.
Anti-CLTA4 Immunotherapy Achieves Antitumor Effects in Small Study of Hepatitis C-Related Hepatocellular CarcinomaJuly 30, 2013
Immunotherapy targeting the CLTA4 protein in HCV-related HCC demonstrated modest extended survival in a disease that has a high mortality rate.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
- Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder